Cartesian Therapeutics, Inc. (RNAC)

Last Closing Price: 6.91 (2026-04-21)

Net Income (Quarterly)

Net Income: Company's net profit or loss after all revenues, income items, and expenses have been accounted for. Because this figure is given after preferred dividend expense, it is the net income value allotted to common shareholders.

Cartesian Therapeutics, Inc. (RNAC) had Net Income of $-89.95M for the most recently reported fiscal quarter, ending 2025-12-31.

Figures for fiscal quarter ending 2025-12-31
Income Statement Financials
$0.95M
Net Income
$-89.95M
--
$0.95M
$79.59M
$-78.64M
$-23.13M
$-101.77M
$-101.77M
$-92.58M
$-92.58M
$-92.58M
$-92.58M
$-78.64M
$-78.03M
25.97M
25.97M
$-3.47
$-3.46
Balance Sheet Financials
$129.28M
$12.19M
$167.13M
$296.41M
$14.94M
--
$407.71M
$422.65M
$-126.24M
$-174.40M
$-126.24M
26.01M
Cash Flow Statement Financials
$-73.94M
$-5.45M
$-8.05M
$214.28M
$126.87M
$-87.41M
$10.52M
--
--
Fundamental Metrics & Ratios
8.65
--
--
--
--
100.00%
-8304.01%
-8304.01%
--
-10746.46%
-9498.21%
$-79.39M
--
--
--
0.00
--
0.85
105.97
73.33%
53.08%
-31.23%
73.33%
$-4.85
$-3.06
$-2.85